Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction

  • Liu, Qinghui
  • Hovden, Ivar T
  • MacIntosh, Bradley J
  • Grødem, Edvard O.S.
  • Brandal, Peter
  • Sederevicius, Donatas
  • Skogen, Karoline
  • Schellhorn, Till
  • Bjornerud, Atle
  • Emblem, Kyrre E.
  • Fuster García, Elíes|||0000-0002-0716-8960
  • López-Mateu, Carlos
[EN] Diffuse gliomas are malignant brain tumors that grow widespread through the brain. The complex interactions between neoplastic cells and normal tissue, as well as the treatment-induced changes often encountered, make glioma tumor growth modeling challenging. In this paper, we present a novel end-to-end network capable of future predictions of tumor masks and multi-parametric magnetic resonance images (MRI) of how the tumor will look at any future time points for different treatment plans. Our approach is based on cutting-edge diffusion probabilistic models and deep-segmentation neural networks. We included sequential multi-parametric MRI and treatment information as conditioning inputs to guide the generative diffusion process as well as a joint segmentation process. This allows for tumor growth estimates and realistic MRI generation at any given treatment and time point. We trained the model using real-world postoperative longitudinal MRI data with glioma tumor growth trajectories represented as tumor segmentation maps over time. The model demonstrates promising performance across various tasks, including generating high-quality multi-parametric MRI with tumor masks, performing time-series tumor segmentations, and providing uncertainty estimates. Combined with the treatment-aware generated MRI, the tumor growth., This work was supported by the European Union s Horizon 2020 Programme: ERC (European Research Council) Grant Agreement No. 758657-ImPRESS, Helse Sør-Øst Regional Health Authority grants 2021057, 2017073, the Research Council of Norway grants 325971, 261984, and grant PID2021-127110OA-I00 funded by MCIN/AEI/10.13039/501100011033 from Agencia de Investigación de Espana and by ERDF (European Regional Development Fund) A way of making Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Decreased tissue stiffness in glioblastoma by MR elastography is associated with increased cerebral blood flow

  • Svensson, Siri Fløgstad
  • Latysheva, Anna
  • Fraser-Green, Jorunn
  • Nordhoy, Wibeke
  • Darwish, Omar Isam
  • Hovden, Ivar Thokle
  • Holm, Sverre
  • Vik-Mo, Einar O.
  • Sinkus, Ralph
  • Emblem, Kyrre Eeg
  • Fuster García, Elíes|||0000-0002-0716-8960
[EN] Purpose: Understanding how mechanical properties relate to functional changes in glioblastomas may help explain different treatment response between patients. The aim of this study was to map differences in biome-chanical and functional properties between tumor and healthy tissue, to assess any relationship between them and to study their spatial distribution. Methods: Ten patients with glioblastoma and 17 healthy subjects were scanned using MR Elastography, perfusion and diffusion MRI. Stiffness and viscosity measurements G' and G '', cerebral blood flow (CBF), apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were measured in patients' contrast-enhancing tumor, necrosis, edema, and gray and white matter, and in gray and white matter for healthy subjects. A regression analysis was used to predict CBF as a function of ADC, FA, G' and G ''. Results: Median G' and G' ' in contrast-enhancing tumor were 13% and 37% lower than in normal-appearing white matter (P < 0.01), and 8% and 6% lower in necrosis than in contrast-enhancing tumor, respectively (P < 0.05). Tumors showed both inter-patient and intra-patient heterogeneity. Measurements approached values in normalappearing tissue when moving outward from the tumor core, but abnormal tissue properties were still present in regions of normal-appearing tissue. Using both a linear and a random-forest model, prediction of CBF was improved by adding MRE measurements to the model (P < 0.01). Conclusions: The inclusion of MRE measurements in statistical models helped predict perfusion, with stiffer tissue associated with lower perfusion values., Grant Support: We gratefully acknowledge support from the European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, Research and Innovation Grant Agreements No. 668039-FORCE and Marie Sklodowska-Curie grant agreement (No 844646-GLIOHAB), South-Eastern Norway Regional Health Authority (Grant Agreement No. 2017073, 2013069 and 2021057), The Research Council of Norway FRIPRO (Grant Agreement No. 261984), the National Institutes of Health R21 grant (Grant Agreement No. EB030757), and the German Research Foundation (DFG, SCHR 1542/1-1).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The prognostic relevance of a gene expression signature in MRI-defined highly vascularized glioblastoma

  • Montosa-Micó, Víctor
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Gómez-Mahiques, María
  • López-Mateu, Carlos
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Álvarez-Torres, María del Mar
  • Burgos-Panadero, Rebeca
[EN] Background The vascular heterogeneity of glioblastomas (GB) remains an important area of research, since tumor progression and patient prognosis are closely tied to this feature. With this study, we aim to identify gene expression profiles associated with MRI-defined tumor vascularity and to investigate its relationship with patient prognosis. Methods The study employed MRI parameters calculated with DSC Perfusion Quantification of ONCOhabitats glioma analysis software and RNA-seq data from the TCGA-GBM project dataset. In our study, we had a total of 147 RNA-seq samples, which 15 of them also had MRI parameter information. We analyzed the gene expression profiles associated with MRI-defined tumor vascularity using differential gene expression analysis and performed Log-rank tests to assess the correlation between the identified genes and patient prognosis. Results The findings of our research reveal a set of 21 overexpressed genes associated with the high vascularity pattern. Notably, several of these overexpressed genes have been previously implicated in worse prognosis based on existing literature. Our log-rank test further validates that the collective upregulation of these genes is indeed correlated with an unfavorable prognosis. This set of genes includes a variety of molecules, such as cytokines, receptors, ligands, and other molecules with diverse functions. Conclusions Our findings suggest that the set of 21 overexpressed genes in the High Vascularity group could potentially serve as prognostic markers for GB patients. These results highlight the importance of further investigating the relationship between the molecules such as cytokines or receptors underlying the vascularity in GB and its observation through MRI and developing targeted therapies for this aggressive disease., This work was funded by Grant PID2021-127110OA-I00 (PROGRESS) funded by MCIN/AEI/10.13039/501100011033 and by ERDF, Beca Margarita Salas funded by Ministerio de Ciencia, Innovacion y Universidades. Grant ID: MS21-046, SINUE (INNEST/2022/87 Agencia Valenciana de la Innovacion), ALBATROSS (PID2019-104978RB-I00), Programa INVESTIGO (INVEST/2022/298) and Grant CIAICO/2022/064 (Lalaby-Glio) funded by Generalitat Valenciana.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Interpreting deep learning models for glioma survival classification using visualization and textual explanations.

  • Osadebey, Michael
  • Liu, Qinghui
  • Emblem, Kyrre E.
  • Fuster García, Elíes|||0000-0002-0716-8960
[EN] Background Saliency-based algorithms are able to explain the relationship between input image pixels and deeplearning model predictions. However, it may be difcult to assess the clinical value of the most important image features and the model predictions derived from the raw saliency map. This study proposes to enhance the interpret¿ ability of saliency-based deep learning model for survival classifcation of patients with gliomas, by extracting domain knowledge-based information from the raw saliency maps. Materials and methods Our study includes presurgical T1-weighted (pre- and post-contrast), T2-weighted and T2-FLAIR MRIs of 147 glioma patients from the BraTs 2020 challenge dataset aligned to the SRI 24 anatomical atlas. Each image exam includes a segmentation mask and the information of overall survival (OS) from time of diag¿ nosis (in days). This dataset was divided into training (n = 118) and validation (n = 29) datasets. The extent of surgi¿ cal resection for all patients was gross total resection. We categorized the data into 42 short (mean µ = 157 days), 30 medium (µ = 369 days), and 46 long (µ = 761 days) survivors. A 3D convolutional neural network (CNN) trained on brain tumour MRI volumes classifed all patients based on expected prognosis of either short-term, mediumterm, or long-term survival. We extend the popular 2D Gradient-weighted Class Activation Mapping (Grad-CAM), for the generation of saliency map, to 3D and combined it with the anatomical atlas, to extract brain regions, brain volume and probability map that reveal domain knowledge-based information. Results For each OS class, a larger tumor volume was associated with a shorter OS. There were 10, 7 and 27 tumor locations in brain regions that uniquely associate with the short-term, medium-term, and long-term survival, respec¿ tively. Tumors located in the transverse temporal gyrus, fusiform, and palladium are associated with short, medium and long-term survival, respectively. The visual and textual information displayed during OS prediction highlights tumor location and the contribution of diferent brain regions to the prediction of OS. This algorithm design feature assists the physician in analyzing and understanding diferent model prediction stages. Conclusions Domain knowledge-based information extracted from the saliency map can enhance the interpret¿ ability of deep learning models. Our fndings show that tumors overlapping eloquent brain regions are associated with short patient survival., This work was supported by The European Union s Horizon 2020 Programmes ERC Grant Agreement No. 758657-ImPRESS, and Marie Sk&#322;odowska-Curie grant agreement (No 844646-GLIOHAB). The Norwegian Cancer Society and the Research Council of Norway Grants 303249, 261984, 325971. South-Eastern Norway Regional Health Authority Grants 2021057, 2013069, 2017073. Elies Fuster-Garcia was supported by Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT

  • Álvarez-Torres, María del Mar
  • Balaña, Carmen
  • Puig, Josep
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Garcia-Gomez, Juan M
[EN] Despite the complete treatment with surgery, chemotherapy and radiotherapy, patients with glioblastoma have a devasting prognosis. Although the role of extending temozolomide treatment has been explored, the results are inconclusive. Recent evidence suggested that tumor vascularity may be a modulating factor in combination with methylation of O6-methylguanine-DNA methyltransferase (MGMT) promotor gene on the effect of temozolomide-based therapies, opening new possibilities for personalized treatments. Before proposing a prospective interventional clinical study, it is necessary to confirm the beneficial effect of the combined effect of MGMT methylation and moderate tumor vascularity, as well as the lack of benefit of temozolomide in patients with a highly vascular tumor.In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (MGMT) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and calculation of relative cerebral blood volume (rCBV), used to define moderate- and high-vascular groups, were performed with the automatic ONCOhabitats method. We assessed the previously proposed rCBV threshold (10.7) and the new calculated ones (9.1 and 9.8) to analyze the association with survival for different populations according to vascularity and MGMT methylation status. We found that patients included in the moderate-vascular group had longer survival when MGMT is methylated (significant median survival difference of 174 days, p = 0.0129*). However, we did not find significant differences depending on the MGMT methylation status for the high-vascular group (p = 0.9119). In addition, we investigated the combined correlation of MGMT methylation status and rCBV with the prognostic effect of the number of temozolomide cycles, and only significant results were found for the moderate-vascular group. In conclusion, there is a lack of benefit of extending temozolomide treatment for patients with high vascular glioblastomas, even presenting MGMT methylation. Preliminary results suggest that patients with moderate vascularity and methylated MGMT glioblastomas would benefit more from prolonged adjuvant chemotherapy., M.A-T was supported by DPI2016-80054-R (Programa Estatal de Promocion del Talento y su Empleabilidad en I+D+i). This work was partially supported by the ALBATROSS project (National Plan for Scientific and Technical Research and Innovation 2017-2020, No. PID2019-104978RB-I00). This study was partially funded by the Fundacio La Marato TV3 (665/C/2013) (http://www.ccma.cat/tv3/marato/projectes-financats/2012/231/ Accessed on 8th September 2021). (JMGG); H2020-SC1-2016-CNECT Project (No. 727560) (JMGG), and H2020-SC1-BHC-2018-2020 (No. 825750) (JMGG). EFG was supported by the European Unions Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 844646 and South-Eastern Norway Regional Health Authority Grant 2021057.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect

  • López-Mateu, Carlos
  • Gómez-Mahiques, María
  • Montosa-Micó, Víctor
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Sederevicius, Donatas
  • Emblem, Kyrre E.
[EN] Background: Glioblastoma (GBM) growth can alter surrounding brain tissue through location-dependent physiological changes. Two main growth phenotypes¿(I) infiltrative, characterized by diffuse invasion with minimal mass effect, and (II) proliferative, characterized by pronounced tissue compression¿are recognized, but their quantitative characterization and prognostic impact remain poorly explored. Purpose: To develop and validate a novel MRI-based biomarker, the Dynamic Infiltration Rate (DIR), that quantitatively assesses the balance between tumor volume expansion and peritumoral compression, and to evaluate its prognostic ability for stratifying patients based on overall survival (OS). Methods: The DIR was defined as the ratio between tumor-volume enlargement and mass-effect-induced peritumoral compression. Technical validation was conducted using synthetic datasets with known ground truth spanning realistic infiltrative-proliferative spectra. Clinically, patients were dichotomized into high- and low-infiltration groups using a threshold optimized by maximizing the log-rank statistic for OS. Prognostic evaluation included multivariate Cox regression adjusted for age, sex, and MGMT methylation status. Results: The synthetic dataset validation demonstrated high concordance with ground truth (R² = 0.89). Clinical evaluation indicated significantly improved OS in the low DIR group (median = 35.2 weeks) compared to the high DIR group (median = 16.0 weeks; p = 0.0001). DIR effectively stratified patients based on survival (log-rank p < 0.001, HR = 2.49) and remained an independent prognostic factor on multivariate analysis (HR = 1.45, 95% CI 1.07¿1.85; p = 0.0159). Conclusions: The DIR is a novel and robust quantitative MRI biomarker capable of distinguishing between proliferative and infiltrative GBM phenotypes, independently predicting OS. Early phenotype identification could facilitate personalized treatment strategies and individualized follow-up scheduling., MCIN/AEI (Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación), Grant/Award Numbers: PID2024156848OB-I00, PID2021-127110OA-I00, PDC2025-165365-I00, FPU23/02431; Generalitat Valenciana, Grant/Award Numbers: INVEST/2022/298 (ProgramaINVESTIGO), CIAICO/2022/064(Lalaby-Glio), INNEST/2022/87(SINUÉ); European Research Council, Grant/Award Numbers: 758657-ImPRESS, 101213953-CHRONOS; Helse Sør-Øst RHF, Grant/Award Numbers: 2021057, 2017073, 2023050; Research Council of Norway, Grant/Award Numbers: 325971, 261984, 303249, 32543, 356066; Norwegian Cancer Society, Grant/Award Number: 309012 - SAFARI; Universitat Politècnica de València, Grant/Award Number: PAID-01-24(Subprogram1)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Quantification of Tissue Compression Identifies High-Grade Glioma Patients with Reduced Survival

  • Fuster García, Elíes|||0000-0002-0716-8960
  • Hovden, Ivar Thokle
  • Fløgstad Svensson, Siri
  • Larsson, Christopher
  • Vardal, Jonas
  • Bjørnerud, Atle
  • Emblem, Kyrre E.
[EN] The compression of peritumoral healthy tissue in brain tumor patients is considered a major cause of the life-threatening neurologic symptoms. Although significant deformations caused by the tumor growth can be observed radiologically, the quantification of minor tissue deformations have not been widely investigated. In this study, we propose a method to quantify subtle peritumoral deformations. A total of 127 MRI longitudinal studies from 23 patients with high-grade glioma were included. We estimate longitudinal displacement fields based on a symmetric normalization algorithm and we propose four biomarkers. We assess the interpatient and intrapatient association between proposed biomarkers and the survival based on Cox analyses, and the potential of the biomarkers to stratify patients according to their survival based on Kaplan¿Meier analysis. Biomarkers show a significant intrapatient association with survival (p < 0.05); however, only compression biomarkers show the ability to stratify patients between those with higher and lower overall survival (AUC = 0.83, HR = 6.30, p < 0.05 for CompCH). The compression biomarkers present three times higher Hazard Ratios than those representing only displacement. Our study provides a robust and automated method for quantifying and delineating compression in the peritumoral area. Based on the proposed methodology, we found an association between lower compression in the peritumoral area and good prognosis in high-grade glial tumors., This work was partially supported by: The European Research Council (ERC) under the European Union's Horizon 2020 (Grant Agreement No 758657), the South-Eastern Norway Regional Health Authority Grants 2017073 and 2013069, the Research Council of Norway Grants 261984 and 325971 (K.E.E.), The European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie (Grant Agreement No 844646), and South-Eastern Norway Regional Health Authority Grant 2021057 (E.F.G.).